Orforglipron Dosage: The FDA-Approved Foundayo Schedule
The exact FDA-approved orforglipron (Foundayo) tablet dosing schedule - starting dose, titration, maximum dose, missed-dose rule - not a grey-market protocol.
The short version
Foundayo (orforglipron) is a once-daily tablet. It starts at 0.8 mg and rises to 2.5 mg, 5.5 mg, 9 mg and 14.5 mg, up to a 17.2 mg maximum. Each dose lasts at least 30 days before the next increase. A prescriber manages the titration. This page gives only what the FDA label says.
- Starting dose is 0.8 mg once daily, titrating in steps up to a 17.2 mg maximum, at least 30 days apart.
- It is a tablet, swallowed whole, with or without food, so there is no reconstitution math for this drug.
- Missing 7 or more consecutive doses means restarting the titration at a lower dose, per the label.
Orforglipron, sold as Foundayo, is dosed as a once-daily tablet. This page gives the FDA-approved titration schedule. Background on the drug, why it is not a peptide, and its boxed warning are on the main orforglipron page.
The approved schedule
| Step | Dose | Timing |
|---|---|---|
| Start | 0.8 mg once daily | At least 30 days |
| Titration | 2.5 mg once daily | At least 30 days |
| Titration | 5.5 mg once daily | At least 30 days |
| Titration | 9 mg once daily | At least 30 days |
| Titration | 14.5 mg once daily | At least 30 days |
| Maximum | 17.2 mg once daily | Ongoing |
Each increase requires at least 30 days on the current dose. That is a floor, not a fixed calendar: the label leaves the pace to the prescriber’s judgment against tolerability and response.
Take it orally, once a day, with or without food, at any time. Swallow the tablet whole. Do not break, crush or chew it.
Missed dose
Take a missed dose as soon as possible, without doubling the next day’s dose to compensate. If 7 or more consecutive daily doses are missed, the label says to restart the escalation schedule at a lower dose rather than resume where treatment left off.
Reconstitution and injection math
Not applicable. Foundayo is a fixed-strength oral tablet, not a vial, so there is no reconstitution or injection-volume arithmetic. The dosage calculator on this site is built for peptide vials rather than tablets.
What is not established
- No published human study varies this schedule. The steps above are the titration FDA reviewed. No separate trial tests a faster titration or a different order of doses.
- A compounded or grey-market product sold under this name has no reviewed schedule of its own. It is a different product from the FDA-approved tablet the label describes.
Who should not use it, and the main risks
Full contraindication, boxed-warning and adverse-reaction detail is on the main orforglipron page. In short:
- It is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- It is not recommended in severe hepatic impairment.
- The most common reactions are gastrointestinal: nausea, constipation, diarrhoea and vomiting.
Related
Where to get Orforglipron legally
Orforglipron is an FDA-approved prescription medicine, so the legal route is a licensed prescriber, in person or by telehealth, and a licensed pharmacy.
How telehealth prescribing works, what it costs and what to check: telehealth peptide prescribing.
Common questions
What is the starting dose of orforglipron (Foundayo)?
The FDA label sets the starting dose at 0.8 mg taken orally once daily, for at least the first 30 days, before any increase.
How does the orforglipron dose increase over time?
The label steps the dose up after at least 30 days on the current dose. The steps are 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg, up to a maximum of 17.2 mg once daily. The prescriber decides each increase based on tolerability and response. It is not a fixed 30-day calendar.
What is the maximum orforglipron dose?
The label sets 17.2 mg once daily as the maximum dose. The trial data behind the approval shows the largest weight-loss effect at this top dose, with smaller effects at each lower step. That is the label's basis for titrating upward rather than starting there.
Does orforglipron need to be taken with food?
No. The label says it can be taken with or without food, at any time of day. Swallow the tablet whole. Do not break, crush or chew it.
What if a dose of orforglipron is missed?
Take the missed dose as soon as possible, but do not double up the next day's dose. If 7 or more consecutive daily doses are missed, restart the dose-escalation schedule at a lower dose instead of resuming at the prior dose.
Is there reconstitution math for orforglipron?
No. Foundayo is an oral tablet at a fixed milligram strength per pill, not a vial requiring reconstitution or an injection-volume calculation. The dosage calculator on this site is built for peptide vials and does not apply to this drug.
Does a compounded or grey-market orforglipron product follow this schedule?
There is no reviewed schedule for one. This titration is specific to Foundayo, the FDA-approved tablet. A product sold outside that approval has not gone through the review that set this schedule. The same FDA warnings about dosing errors and counterfeit product in the unapproved GLP-1 supply chain apply.
References (1 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.FOUNDAYO (orforglipron) tablets - full prescribing information, dosage and administration section: starting dose, titration schedule, maximum dose, missed-dose instructions.- DailyMed, National Library of Medicinelabel